Literature DB >> 16315953

[A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].

Masato Nakamura1, Hiroaki Nagano, Masato Sakon, Tameyoshi Yamamoto, Hideo Ota, Hiroshi Wada, Shinichi Yoshioka, Hitoshi Kato, Bazarragchaa Damdinsuren, Shigeru Marubashi, Atsushi Miyamoto, Yutaka Takeda, Koji Umeshita, Shoji Nakamori, Keizo Dono, Morito Monden.   

Abstract

A 56-year-old male was admitted to our hospital for hepatoma with portal vein thrombus and multiple intrahepatic metastases. He underwent an extended left lobectomy and a partial resection of the liver in May 2002. After two weeks from the surgery, he received intra arterial 5-FU infusion chemotherapy combined with subcutaneous interferon-alpha injection to treat the lesions in the residual liver. Four months after the surgery, hepatic vein tumor thrombus appeared in the remnant liver and it extended to the inferior caval vein. And another 4 months later, multiple pulmonary metastases were detected with computed tomography and they grew rapidly in the view of their sizes and numbers. Because the combined therapy of 5-FU/interferon-alpha was not effective to distant metastases, we started a new regimen of oral administration of TS-1 and a subcutaneous interferon-alpha injection. After 1 treatment cool, hepatic vein thrombus was markedly reduced the size and vascularity in the CT. Multiple pulmonary metastases also decreased in their sizes and numbers. No adverse effect was seen during this treatment. It was suggested that a combination therapy of TS-1 and interferon-alpha may be one of the most effective treatment modalities against advanced HCC with distant metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315953

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Complete cure of a patient with HBV-associated hepatocellular carcinoma with lung metastasis using interferon and survival up to 108 months: A case report and literature review.

Authors:  Fang Wang; Hongmin Lv; Yan Li; Tao Han; Hui Liu; Kefeng Jia; Fang Liu; Yanying Gao; Fengmei Wang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.